KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Receivables - Other (2016 - 2024)

Historic Receivables - Other for Gsk (GSK) over the last 9 years, with Q4 2024 value amounting to $1.1 billion.

  • Gsk's Receivables - Other fell 1519.21% to $1.1 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 billion, marking a year-over-year decrease of 1519.21%. This contributed to the annual value of $1.1 billion for FY2024, which is 1571.89% down from last year.
  • Gsk's Receivables - Other amounted to $1.1 billion in Q4 2024, which was down 1519.21% from $1.3 billion recorded in Q4 2023.
  • In the past 5 years, Gsk's Receivables - Other registered a high of $15.2 billion during Q1 2022, and its lowest value of $1.1 billion during Q4 2024.
  • In the last 5 years, Gsk's Receivables - Other had a median value of $1.4 billion in 2020 and averaged $3.7 billion.
  • In the last 5 years, Gsk's Receivables - Other crashed by 2409.39% in 2020 and then surged by 2708.19% in 2021.
  • Quarter analysis of 5 years shows Gsk's Receivables - Other stood at $1.3 billion in 2020, then increased by 27.08% to $1.7 billion in 2021, then decreased by 15.74% to $1.4 billion in 2022, then decreased by 9.81% to $1.3 billion in 2023, then fell by 15.19% to $1.1 billion in 2024.
  • Its Receivables - Other was $1.1 billion in Q4 2024, compared to $1.3 billion in Q4 2023 and $1.4 billion in Q4 2022.